Screening for coagulation disorders in patients with ischemic stroke

References

• Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature369(6475), 64–67 (1994).
   PubMed Web of Science ®Google Scholar
• Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb. Haemost.98(3), 530–542 (2007).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med.332(14), 912–917 (1995).
   PubMed Web of Science ®Google Scholar
• Cushman M, Rosendaal FR, Psaty BM et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb. Haemost.79(5), 912–915 (1998).
   PubMed Web of Science ®Google Scholar
• Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am. Heart J.146(6), 948–957 (2003).
   PubMed Web of Science ®Google Scholar
• Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood100(1), 3–10 (2002).
   PubMed Web of Science ®Google Scholar
• Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch. Neurol.61(11), 1652–1661 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood112(1), 19–27 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation99(8), 999–1004 (1999).
   PubMedGoogle Scholar
• Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb. Haemost.87(4), 614–621 (2002).
   PubMedGoogle Scholar
• Rahemtullah A, Van Cott EM. Hypercoagulation testing in ischemic stroke. Arch. Pathol. Lab. Med.131(6), 890–901 (2007).
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin. Thromb. Hemost.33(6), 588–596 (2007).
   PubMed Web of Science ®Google Scholar
• Camerlingo M, Finazzi G, Casto L, Laffranchi C, Barbui T, Mamoli A. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology41(9), 1371–1373 (1991).
   PubMed Web of Science ®Google Scholar
• Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke21(7), 1077–1080 (1990).
   PubMedGoogle Scholar
• Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke32(8), 1793–1799 (2001).
   PubMedGoogle Scholar
• Folsom AR, Rosamond WD, Shahar E et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation100(7), 736–742 (1999).
   PubMed Web of Science ®Google Scholar
• Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N. Engl. J. Med.311(24), 1525–1528 (1984).
   PubMed Web of Science ®Google Scholar
• Lonn E. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction? Curr. Opin. Hematol.14(5), 481–487 (2007).
   Google Scholar
• Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J. Am. Coll. Cardiol.48(5), 914–923 (2006).
   PubMed Web of Science ®Google Scholar
• Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem.50(1), 3–32 (2004).
   PubMed Web of Science ®Google Scholar
• Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA288(16), 2015–2022 (2002).
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J.325(7374), 1202 (2002).
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Is plasma homocysteine a modifiable risk factor for stroke? Nat. Clin. Pract. Neurol.2(1), 26–33 (2006).
   Google Scholar
• Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med.354(15), 1567–1577 (2006).
   PubMed Web of Science ®Google Scholar
• Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA291(5), 565–575 (2004).
   PubMed Web of Science ®Google Scholar
• Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med.354(15), 1578–1588 (2006).
   PubMed Web of Science ®Google Scholar
• Carlsson CM. Lowering homocysteine for stroke prevention. Lancet369(9576), 1841–1842 (2007).
   Google Scholar
• Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA296(22), 2720–2726 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Qin X, Demirtas H et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet369(9576), 1876–1882 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Q, Botto LD, Erickson JD et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation113(10), 1335–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima–media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc. Disord.8, 24 (2008).
   PubMedGoogle Scholar
• Dusitanond P, Eikelboom JW, Hankey GJ et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke36(1), 144–146 (2005).
   PubMed Web of Science ®Google Scholar
• Lim W, Crowther MA. Antiphospholipid antibiodies: a critical review of the literature. Curr. Opin. Hematol.14(5), 494–499 (2007).
   Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4(2), 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin. Thromb. Hemost.34(3), 274–281 (2008).
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev.22(2), 93–105 (2008).
   PubMed Web of Science ®Google Scholar
• Tuhrim S, Rand JH, Wu XX et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke30(8), 1561–1565 (1999).
   Google Scholar
• Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke23(2), 189–193 (1992).
   PubMedGoogle Scholar
• Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol.8(11), 998–1005 (2009).
   PubMed Web of Science ®Google Scholar
• Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet339(8791), 451–453 (1992).
   PubMed Web of Science ®Google Scholar
• Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke31(6), 1289–1293 (2000).
   PubMed Web of Science ®Google Scholar
• Levine SR, Brey RL, Tilley BC et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA291(5), 576–584 (2004).
   PubMed Web of Science ®Google Scholar
• Brey RL, Abbott RD, Curb JD et al. β2-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke32(8), 1701–1706 (2001).
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117(12), 997–1002 (1992).
   PubMed Web of Science ®Google Scholar
• Janardhan V, Wolf PA, Kase CS et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke35(3), 736–741 (2004).
   Google Scholar
• Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med.311(8), 501–505 (1984).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Power DA et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke35(10), 2300–2305 (2004).
   PubMedGoogle Scholar
• Danesh J, Lewington S, Thompson SG et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA294(14), 1799–1809 (2005).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke40(5), 1549–1552 (2009).
   PubMed Web of Science ®Google Scholar
• Siegerink B, Rosendaal FR, Algra A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J. Thromb. Haemost.7(3), 385–390 (2009).
   Google Scholar
• Cheung EY, Bos MJ, Leebeek FW et al. Variation in fibrinogen FGG and FGA genes and risk of stroke: the Rotterdam Study. Thromb. Haemost.100(2), 308–313 (2008).
   Google Scholar
• Bernard TJ, Goldenberg NA, Armstrong-Wells J, Amlie-Lefond C, Fullerton HJ. Treatment of childhood arterial ischemic stroke. Ann. Neurol.63(6), 679–696 (2008).
   PubMed Web of Science ®Google Scholar
• Strater R, Becker S, von Eckardstein A et al. Prospective assessment of risk factors for recurrent stroke during childhood – a 5-year follow-up study. Lancet360(9345), 1540–1545 (2002).
   PubMed Web of Science ®Google Scholar
• Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch. Dis. Child.90(4), 402–405 (2005).
   PubMed Web of Science ®Google Scholar
• Barreirinho S, Ferro A, Santos M et al. Inherited and acquired risk factors and their combined effects in pediatric stroke. Pediatr. Neurol.28(2), 134–138 (2003).
   PubMed Web of Science ®Google Scholar
• Brey RL. Antiphospholipid antibodies in young adults with stroke. J. Thromb. Thrombolysis20(2), 105–112 (2005).
   PubMed Web of Science ®Google Scholar
• Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA284(1), 72–78 (2000).
   PubMed Web of Science ®Google Scholar
• Aznar J, Mira Y, Vaya A et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb. Haemost.91(5), 1031–1034 (2004).
   PubMedGoogle Scholar
• Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J. Thromb. Haemost.3(6), 1213–1217 (2005).
   PubMed Web of Science ®Google Scholar
• Pezzini A, Grassi M, Iacoviello L et al. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J. Neurol. Neurosurg. Psychiatry78(3), 271–276 (2007).
   PubMedGoogle Scholar
• Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica91(6), 844–847 (2006).
   PubMed Web of Science ®Google Scholar
• Rosing J, Middeldorp S, Curvers J et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet354(9195), 2036–2040 (1999).
   PubMed Web of Science ®Google Scholar
• Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception73(4), 336–343 (2006).
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Montagnana M, Salvagno GL, Targher G, Guidi GC. Inherited and acquired risk factors for arterial ischemic stroke in childhood. J. Thromb. Thrombolysis27(2), 239–248 (2009).
   Google Scholar
• Weber R, Goertler M, Benemann J, Diener HC, Weimar C. Prognosis after cryptogenic cerebral ischemia in patients with coagulopathies. Cerebrovasc. Dis.28(6), 611–617 (2009).
   PubMed Web of Science ®Google Scholar
• Haapaniemi E, Helenius J, Jakovljevic D et al. Ischaemic stroke patients with heterozygous factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease. Thromb. Haemost.101(1), 145–150 (2009).
   Google Scholar
• Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke37(2), 577–617 (2006).
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis.25(5), 457–507 (2008).
   PubMed Web of Science ®Google Scholar
• Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl,), S630–S669 (2008).
   PubMedGoogle Scholar
• Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA294(6), 706–715 (2005).
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med.349(12), 1133–1138 (2003).
   PubMed Web of Science ®Google Scholar
• Schaumburg H, Kaplan J, Windebank A et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N. Engl. J. Med.309(8), 445–448 (1983).
   PubMed Web of Science ®Google Scholar
• Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), S645–S687 (2004).
   PubMed Web of Science ®Google Scholar
• Pruissen DM, Kappelle LJ, Algra A. Polymorphisms and Risk of Ischemic Stroke (POLARIS) study: rationale and design. Eur. Neurol.51(1), 30–34 (2004).
   Google Scholar